New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond

Taylor and Francis Group, Expert Review of Hematology, 8(14), p. 741-750, 2021

Journal article published in 2021 by Jessica Caro, Catherine Diefenbach

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by